Takahiro Karasaki1, Guangliang Qiang1,2, Masaki Anraku1, Yanbin Sun1,3, Aya Shinozaki-Ushiku4, Eiichi Sato5, Kosuke Kashiwabara6, Kazuhiro Nagayama1, Jun-Ichi Nitadori1, Masaaki Sato1, Tomohiro Murakawa1,7, Kazuhiro Kakimi8, Masashi Fukayama4, Jun Nakajima1. 1. Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 2. Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China. 3. Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, China. 4. Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 5. Department of Pathology (Medical Research Center), Institute of Medical Science, Tokyo Medical University, Tokyo, Japan. 6. Department of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan. 7. Department of Thoracic Surgery, Kansai Medical University, Hirakata, Japan. 8. Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, Japan.
Abstract
BACKGROUND: Clinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4+ lymphocytes and their prognostic impact in lung cancer. We hypothesized that high CCR4 expression in the tumor microenvironment would be associated with a poor prognosis and would act as a biomarker in lung adenocarcinoma. METHODS: First, the prognostic impact of CCR4 gene expression was explored using pooled data from public transcriptomic databases with online survival analysis software. Second, tissue microarrays (TMAs) were constructed from resected lung adenocarcinoma specimens from tumors up to 3 cm in size. The density of CCR4+ lymphocytes infiltrating the tumor was then assessed by immunohistochemistry and related to survival. Confounding factors were controlled for by multivariate analysis using the Cox proportional hazards model. RESULTS: Higher than median expression of the CCR4 gene was identified as an independent poor prognostic factor for overall survival (OS) by multivariate analysis of 720 lung adenocarcinoma patients in the public databases [HR =1.55 (95% CI: 1.03-2.35), P=0.037]. Consistent with this, high CCR4+ tumor-infiltrating lymphocyte (TIL) density was found to be an independent poor prognostic factor for both OS [HR =2.24 (1.01-5.34), P=0.049] and recurrence-free survival (RFS) [HR =2.20 (1.16-4.39), P=0.017] in the patients from whom TMA were obtained (n=180). Age, male gender, predominantly non-lepidic histological subtype, nodal involvement, and low CD8+ TIL density were also independent poor prognostic factors. However, FOXP3 gene expression and Foxp3+ lymphocyte infiltration did not possess any prognostic value in either study. CONCLUSIONS: High CCR4 expression in the tumor microenvironment may be a poor prognostic factor in lung adenocarcinoma. Patients with high CCR4+ lymphocyte infiltration may have a poor prognosis and thus be suitable candidates for clinical trials of anti-CCR4 antibody treatment.
BACKGROUND: Clinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4+ lymphocytes and their prognostic impact in lung cancer. We hypothesized that high CCR4 expression in the tumor microenvironment would be associated with a poor prognosis and would act as a biomarker in lung adenocarcinoma. METHODS: First, the prognostic impact of CCR4 gene expression was explored using pooled data from public transcriptomic databases with online survival analysis software. Second, tissue microarrays (TMAs) were constructed from resected lung adenocarcinoma specimens from tumors up to 3 cm in size. The density of CCR4+ lymphocytes infiltrating the tumor was then assessed by immunohistochemistry and related to survival. Confounding factors were controlled for by multivariate analysis using the Cox proportional hazards model. RESULTS: Higher than median expression of the CCR4 gene was identified as an independent poor prognostic factor for overall survival (OS) by multivariate analysis of 720 lung adenocarcinoma patients in the public databases [HR =1.55 (95% CI: 1.03-2.35), P=0.037]. Consistent with this, high CCR4+ tumor-infiltrating lymphocyte (TIL) density was found to be an independent poor prognostic factor for both OS [HR =2.24 (1.01-5.34), P=0.049] and recurrence-free survival (RFS) [HR =2.20 (1.16-4.39), P=0.017] in the patients from whom TMA were obtained (n=180). Age, male gender, predominantly non-lepidic histological subtype, nodal involvement, and low CD8+ TIL density were also independent poor prognostic factors. However, FOXP3 gene expression and Foxp3+ lymphocyte infiltration did not possess any prognostic value in either study. CONCLUSIONS: High CCR4 expression in the tumor microenvironment may be a poor prognostic factor in lung adenocarcinoma. Patients with high CCR4+ lymphocyte infiltration may have a poor prognosis and thus be suitable candidates for clinical trials of anti-CCR4 antibody treatment.
Authors: Tom Donnem; Sigurd M Hald; Erna-Elise Paulsen; Elin Richardsen; Samer Al-Saad; Thomas K Kilvaer; Odd Terje Brustugun; Aslaug Helland; Marius Lund-Iversen; Mette Poehl; Karen Ege Olsen; Henrik J Ditzel; Olfred Hansen; Khalid Al-Shibli; Yury Kiselev; Torkjel M Sandanger; Sigve Andersen; Francesco Pezzella; Roy M Bremnes; Lill-Tove Busund Journal: Clin Cancer Res Date: 2015-02-13 Impact factor: 12.531
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Chiara Berlato; Moddasar N Khan; Tiziana Schioppa; Richard Thompson; Eleni Maniati; Anne Montfort; Maryam Jangani; Monica Canosa; Hagen Kulbe; Urs B Hagemann; Alexander R Duncan; Laura Fletcher; Robert W Wilkinson; Thomas Powles; Sergio A Quezada; Frances R Balkwill Journal: J Clin Invest Date: 2017-01-30 Impact factor: 14.808
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Kurt A Schalper; Jason Brown; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Vamsidhar Velcheti; Konstantinos N Syrigos; Roy S Herbst; David L Rimm Journal: J Natl Cancer Inst Date: 2015-02-03 Impact factor: 11.816
Authors: Erin A Marshall; Kevin W Ng; Sonia H Y Kung; Emma M Conway; Victor D Martinez; Elizabeth C Halvorsen; David A Rowbotham; Emily A Vucic; Adam W Plumb; Daiana D Becker-Santos; Katey S S Enfield; Jennifer Y Kennett; Kevin L Bennewith; William W Lockwood; Stephen Lam; John C English; Ninan Abraham; Wan L Lam Journal: Mol Cancer Date: 2016-10-27 Impact factor: 27.401
Authors: Yinjie Gao; Michelle M Stein; Matthew Kase; Amy L Cummings; Ramit Bharanikumar; Denise Lau; Edward B Garon; Sandip P Patel Journal: Cancer Immunol Immunother Date: 2022-07-26 Impact factor: 6.630
Authors: Anthony DiNatale; Maria Sofia Castelli; Bradley Nash; Olimpia Meucci; Alessandro Fatatis Journal: J Cancer Date: 2022-08-27 Impact factor: 4.478
Authors: Ying Wu; Yu-Mei Chang; Gerry Polton; Anneliese J Stell; Balazs Szladovits; Michael Macfarlane; Laureen M Peters; Simon L Priestnall; Nicholas J Bacon; Kelvin Kow; Sarah Stewart; Eshita Sharma; Michelle R Goulart; John Gribben; Dong Xia; Oliver A Garden Journal: Front Oncol Date: 2020-03-06 Impact factor: 6.244